Tübingen-based industry investor SHS acquires minority share in formulation specialist Develco Pharma
Develco specializes in the development, approval and production of innovative and generic specialty drugs and offers a unique and broad set of formulation technologies for orally administered medicines with specific substance-release profiles
Develco operates a state-of-the-art production facility of its own in Germany
Equity investment accelerates the development of new medicines
Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH is investing from its SHS V fund in the Swiss-German specialty drug company Develco Pharma. Founded in 2006 and now with more than 120 employees, the company operates in Switzerland and Schopfheim, Germany, developing and manufacturing orally administered medicines containing known active ingredients in formulations that offer delayed or modified release of active ingredients. Develco has state-of-the-art production operations of its own;